Hemoglobinopathies Market (By Type: Thalassemia, Sickle Cell Disease, Others; By Therapy: Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea, Others; By Distribution Channel: Hospital Pharmacy, Online Providers, Drug Stores and Retail Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Hemoglobinopathies Market 

5.1. COVID-19 Landscape: Hemoglobinopathies Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Hemoglobinopathies Market, By Type

8.1. Hemoglobinopathies Market, by Type, 2023-2032

8.1.1 Thalassemia

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Sickle Cell Disease

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Hemoglobinopathies Market, By Therapy

9.1. Hemoglobinopathies Market, by Therapy, 2023-2032

9.1.1. Monoclonal Antibody Medication

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. ACE inhibitors

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Hydroxyurea

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Hemoglobinopathies Market, By Distribution Channel 

10.1. Hemoglobinopathies Market, by Distribution Channel, 2023-2032

10.1.1. Hospital Pharmacy

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Online Providers

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Drug Stores and Retail Pharmacy

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Hemoglobinopathies Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2020-2032)

11.1.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.5.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Therapy (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 12. Company Profiles

12.1. Sangamo Therapeutics, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Global Blood Therapeutics, Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. bluebird bio, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Emmaus Life Sciences Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Pfizer, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Novartis AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Prolong Pharmaceuticals, LLC

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Bioverativ Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Gamida Cell

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Celgene Corporation

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample